Edgewise completes $1.55B sale of muscular dystrophy program to Servier; up to $2.65B total

Edgewise Therapeutics, Inc.

Sold sevasemten and muscular dystrophy program to Servier for $1.55B upfront plus up to $1.1B in milestones ($2.65B total).
Company refocuses on cardiovascular pipeline: EDG-7500 (HCM), EDG-15400 (HFpEF), and EDG-003 (undisclosed).
Upfront proceeds expected to fully fund EDG-7500 development through potential approval.
Plans to initiate Phase 3 trial for EDG-7500 in Q4 2026 and Phase 2 trial for EDG-15400 in HFpEF.
Core muscular dystrophy employees offered positions at Servier to ensure continuity.

Featured in Daily 8-K Digest

Selected #3 for 2026-07-13. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.